The U.S. Food and Drug Administration (FDA) has officially cleared Wellcovorin, a decades-old medication, for an exceedingly rare neurological syndrome—a sharp pivot from earlier high-profile claims regarding its potential as a treatment for autism.
A narrowed clinical scope Despite projections made last September by FDA officials that the drug could benefit “hundreds of thousands of children” with autism, the final approval is restricted to cerebral folate deficiency. This ultra-rare condition has been documented in fewer than 50 individuals globally. The authorization applies specifically to patients with a confirmed genetic variant who exhibit developmental delays alongside autistic features.
An unconventional regulatory path Originally developed by GSK to mitigate chemotherapy side effects, Wellcovorin was discontinued in 1997 following the rise of generic alternatives. In an unusual move, the FDA reached out to GSK, requesting a new application based on existing case reports and literature rather than standard, prospective clinical trials. This bypassed traditional drug development protocols that require rigorous, agency-supervised studies.
Scientific skepticism and public impact The administration’s focus on the drug was fueled by theories linking folate transport blockages to autism. However, clinical evidence remains thin; studies conducted to date have been small-scale, and one pivotal study was recently retracted.
Despite the limited data, previous public endorsements triggered a 71% surge in prescriptions as parents sought the drug “off-label.” Many physicians remains hesitant to prescribe the treatment for autism, citing a lack of proven efficacy and potential risks, including anaphylaxis, skin rashes, and spontaneous fluctuations in body temperature.